Synergy Pharmaceuticals Inc (NASDAQ: SGYP) shares climbed 4.5% to $8.58 following the announcement of positive results in second Phase 3 trial of plecanatide in patients with CIC. Share volume was 16.3 million, compared to an all-day average of 5.7 million
